Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
-
Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S.New Clinical Data Highlighting Five-year...
-
REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
-
Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board:...
-
Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32% Year-over-YearFirst Half 2023 Adjusted EBITDA of $9.9...
-
REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
-
The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 ...
-
Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-YearSolid First Quarter Results and Expected...
-
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a...
-
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a...